Literature DB >> 7736898

A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis.

P A Coates1, R L Ollerton, S D Luzio, I Ismail, D R Owens.   

Abstract

The reported glucose and immunoreactive insulin (IRI) responses to oral and intravenous glucose in subjects with Type 2 diabetes have not always been consistent. This may have resulted from variations in the method of glucose administration, the ethnic backgrounds of subjects, the diagnostic criteria applied, the duration of the disease or IRI assay methods. The use of a mixed meal rather than glucose has been shown to provide a more physiological stimulus to the pancreatic beta-cell due to both glucose and non-glucose secretagogues. We have analysed the metabolic and hormonal responses of 188 newly diagnosed Caucasian subjects with Type 2 diabetes and 38 non-diabetic subjects to a 500 kcal mixed meal. The diabetic subjects were stratified according to fasting plasma glucose (FPG) (< 9, 9-12, 12-15 and > or = 15 mmol/l) and body mass index (BMI) (< 26.5, 26.5-30 and > or = 30 kg/m2). Increasing FPG was associated with higher peak glucose concentrations and increasing failure to achieve basal glucose levels by 4 h. Median fasting IRI concentrations were similar to those of normal subjects, but all diabetic subjects had reduced early-phase insulin secretion. Diabetic subjects with FPG < 9 mmol/l showed augmented IRI area under the curve (AUC) at 2 and 4 h, whereas those with FPG > 9 mmol/l had progressive falls in IRI AUC to below that of the normal subjects (P < 0.0001 for the trend). Peak IRI concentrations declined progressively with increasing FPG. Despite equivalent glucose exposure simple trends of increasing AUC, IRI with increasing BMI were statistically significant (P < 0.001, P < 0.02, P < 0.001 and P < 0.01, respectively for each FPG group). Both fasting and AUC non-esterified fatty acid concentrations increased significantly with FPG regardless of BMI (P < 0.001 for the trends). These results using a more physiological mixed meal challenge in a large number of recently diagnosed Type 2 diabetic subjects demonstrate a marked and increasing loss of beta-cell secretory function with increasing fasting hyperglycaemia aggravated by insulin resistance with increasing obesity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7736898     DOI: 10.1016/0168-8227(94)90059-0

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  5 in total

Review 1.  Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making.

Authors:  Gerhard H Scholz; Holger Fleischmann
Journal:  Ther Adv Endocrinol Metab       Date:  2014-10       Impact factor: 3.565

2.  Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus - a pilot study.

Authors:  G Shanmugasundar; Anil Bhansali; Rama Walia; Pinaki Dutta; Vimal Upreti
Journal:  Indian J Med Res       Date:  2012       Impact factor: 2.375

3.  Point: postprandial glucose levels are a clinically important treatment target.

Authors:  Antonio Ceriello
Journal:  Diabetes Care       Date:  2010-08       Impact factor: 17.152

4.  Emerging role of insulin with incretin therapies for management of type 2 diabetes.

Authors:  Rupa Ahluwalia; Jiten Vora
Journal:  Diabetes Ther       Date:  2011-07-21       Impact factor: 2.945

5.  The pathophysiology of glucose intolerance in newly diagnosed, untreated T2DM.

Authors:  Gareth J Dunseath; Stephen D Luzio; Rajesh Peter; David R Owens
Journal:  Acta Diabetol       Date:  2021-09-24       Impact factor: 4.280

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.